FDA warned India-based contract testing lab Tentamus over destroyed and backdated lab records and limited inspection access.
What happened
FDA inspected Tentamus India's contract testing laboratory in Hyderabad from August 14 to 22, 2025. Investigators found two garbage bags of torn analytical records and impurity method validation spreadsheets, staff recording CGMP data in personal diaries, blank preventive maintenance forms pre-signed and dated, and a lab manager signing and backdating records. The firm also tried to remove the garbage bags, withheld requested documents, and a manager said senior management told him not to share audit details with the investigator.
What FDA found
The quality control unit did not keep complete records: torn analytical records and method validation data were found in garbage bags, and staff used unofficial personal diaries for CGMP data.
21 CFR 211.22The firm did not properly investigate out-of-specification results; a Total Aerobic Microbial Count reported as 'too numerous to count' was later re-issued as passing with no investigation or supporting data.
21 CFR 211.192Required laboratory control records were not written at the time the work was done: blank maintenance forms were pre-signed and dated, and records were backdated.
21 CFR 211.160(a)The firm delayed and limited access to records during the inspection, including attempting to remove documents and not providing requested audit forms.
Section 501(j) of the FD&C Act, 21 U.S.C. 351(j)
What FDA wants
FDA tells the firm to respond in writing within 15 working days with a full data integrity investigation and risk assessment, a corrective action and management strategy, a quality unit remediation plan, a list of all method validations since 2022 with a third-party assessment, and a retrospective review of invalidated out-of-specification results.
Who should pay attention
- drug manufacturers that use Tentamus India as a contract testing laboratory
- US applicants whose drug applications rely on this lab's test data
- other contract testing labs handling CGMP data
This is a summary. Read the original letter on fda.gov.